NXTC Q3 2025 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$36M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$9M

Net Income

-$9M

EPS (Diluted)

$-3.22

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$600,000

Balance Sheet

Total Assets

$40M

Total Liabilities

$16M

Stockholders' Equity

$24M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$9M	-$12M	+28.4%
Net Income	-$9M	-$12M	+25.3%